MOST NOTEWORTHY:

• JP Morgan lowered its rating on Intel (NASDAQ:INTC) to Neutral from Overweight, as their checks indicate a late-quarter slowdown for Intel in order rates from the PC end market, which offset the upside the company experienced in earlier in Q4.
  
• Banc of America downgraded shares of Respironics (NASDAQ:RESP) to Neutral from Buy to reflect the acquisition by Philips (NYSE:PHG).
  
• Friedman Billings downgraded First Horizon (NYSE:FHN) to Underperform from Market Perform, citing its exposure to home equity and construction loans and mortgage banking operations. The firm adds that it expects the company to cut its quarterly dividend.

• JP Morgan removed General Motors (NYSE:GM) from its Focus List.
  
• Merrill downgraded Hess Corp (NYSE:HES) to Neutral from Buy.
  
• Lehman downgraded Westlake Chemical (NYSE:WLK) to Equal Weight from Overweight.

Analyst downgrades: INTC, RESP and FHN originally appeared on BloggingStocks on Fri, 04 Jan 2008 11:43:00 EST. Please see our terms for use of feeds.

MOST NOTEWORTHY UPGRADES:

• Hilliard Lyons upgraded Sypris Solutions (NASDAQ: SYPR) to Buy from Neutral on valuation, and expected improvements in the company's Industrial Group and Electronics Group.
  
• TD Newcrest upgraded Quebecor World (NYSE: IQW) to Hold from Reduce, while UBS upgraded Quilmes Industrial (NYSE: LQU) to Neutral from Sell.

• Respironics Inc. (NASDAQ: RESP) was downgraded to Market Perform from Outperform by BMO Capital, following the company's acquisition by Philips.
  
• Think Equity downgraded Nanophase Technologies (NASDAQ: NANX) to Accumulate from Buy, citing checks that indicate sales for architectural coatings remain sluggish.
  
• Golden Telecom (NASDAQ: GLDN) was lowered to Equal Weight from Overweight by Morgan Stanley.
  
• First Horizon National Corp. (NYSE: FHN) was downgraded to Sell from Hold on Friday by Sandler, O'Neill & Partners.

Analyst upgrades and downgrades originally appeared on BloggingStocks on Mon, 24 Dec 2007 10:50:00 EST. Please see our terms for use of feeds.

Continue reading Philips solidifies health care presence with Respironics buy

Philips solidifies health care presence with Respironics buy originally appeared on BloggingStocks on Fri, 21 Dec 2007 19:39:00 EST. Please see our terms for use of feeds.

Respironics (NASDAQ: RESP) will be acquired by Philips (NYSE: PHG) for $66 in cash per cash. RESP, a provider of treatments for Obstructive Sleep Apnea, closed at $53.61. RESP over all option implied volatility of 28 is near its 26-week average according to Track Data, suggesting non-directional risk.

Genentech (NYSE: DNA) closed at $67.96. DNA will report EPS on January 14th. DNA January option implied volatility of 30 is above its 26-week average of 26 according to Track Data, suggesting larger price risk.

Options Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Options update: Respironics volatility flat into PHG acquiring it for $5.1 billion originally appeared on BloggingStocks on Fri, 21 Dec 2007 10:43:00 EST. Please see our terms for use of feeds.

Continue reading Before the bell: Futures up after RIM reports, Merrill news

Before the bell: Futures up after RIM reports, Merrill news originally appeared on BloggingStocks on Fri, 21 Dec 2007 07:45:00 EST. Please see our terms for use of feeds.

People who have sleep apnea stop breathing for a few seconds during the sleep cycle. That jolts the body awake to start breathing again and normally happens several times a night. Sufferers are chronically tired and some face life-threatening conditions. An estimated 12 million Americans are affected. There is a firm in Murrysville, Pennsylvania that makes medical equipment designed to help patients deal with this condition.

Respironics Inc. (NASDAQ: RESP) specializes in making devices for treating disorders characterized by the cessation of breathing during sleep. Products include continuous positive airway pressure systems, invasive and noninvasive ventilators, oxygen concentrators and peak-flow meters. The company also offers drug-delivery systems for patients with asthma, monitoring systems for sudden infant death syndrome, and treatment tools for infant jaundice. Customers are primarily home medical equipment providers and hospitals.

The firm pleased investors last week, when it reported fiscal Q4 EPS of fifty cents and revenues of $332.4 million. Analysts had expected 48 cents and $322.1 million. Management also guided FY08 EPS to $1.90-$1.98 ($1.91 consensus) and FY08 revenues to $1.345-$1.375 billion ($1.35 billion consensus). The share price popped on the news and has since been consolidating the gain in a bullish "flag" pattern. Prices frequently exit flags moving in the same direction they were traveling when they entered them. In this case, that would be to the upside.

Brokers recommend the stock with five "strong buys," two "buys" and one "hold." The RESP Price to Book ratio (3.95), Sales Growth rate (18.40%), EPS Growth rate (24.90%), Return on Assets (10.90%) and Return on Investment (13.63%) compare favorably with industry, sector and S&P 500 averages. Institutions hold about 79% of the outstanding shares. The stock is one of those used to calculate the S&P 600 SmallCap Index. Over the past 52 weeks, it has traded between $33.04 and $47.64. A stop-loss of $40.25 looks good here.

Larry Schutts is a contributing editor for Theflyonthewall.com and the Vice-President of Stockwinners.com.

Respironics: Setting the pace in the sleep and respiratory market originally appeared on BloggingStocks on Thu, 02 Aug 2007 13:05:00 EST. Please see our terms for use of feeds.